Investment Overview
CroíValve, a Trinity College Dublin spinout and clinical-stage medical device company, has expanded its Series B financing through:
• $20 million Series B expansion financing
• $7 million in European Innovation Council (EIC) and DTIF grant funding
This brings:
• Total Series B financing to $36 million
• Total new capital to $43 million
New investors include:
• BGF
• European Innovation Council Fund
Existing investors including MedTech Syndicate also participated.
The financing will support expansion of the company’s TANDEM II clinical study across the United States and Europe.
Strategic Relevance for GAP Leaders
CroíValve illustrates a highly effective university commercialization pathway:
• Academic innovation → spinout formation
• Early translational support and venture investment
• Clinical validation through multicenter studies
• Capital stacking through venture and grant funding
• Progression toward regulatory approval and commercial launch
Importantly, the company combines both dilutive capital and non-dilutive innovation funding, reducing financing risk while accelerating clinical development.
For university venture leaders, the case demonstrates how medtech companies often require multiple layers of support over extended development cycles, making strategic partnerships and diversified funding sources critical to success.
Innovation & Technology
CroíValve is developing the DUO™ Adapt System, a novel transcatheter therapy for treating tricuspid regurgitation (TR).
Unlike conventional approaches, the DUO™ system:
• Preserves native heart anatomy
• Avoids contact with critical right-heart structures
• Simplifies procedural complexity
• Treats patients with anatomies unsuitable for competing devices
The technology introduces a new category known as Adaptive Coaptation, allowing the device to adapt to individual patient anatomy and effectively treat leaks as large as 35mm.
Early clinical results have demonstrated significant reductions in tricuspid regurgitation among treated patients.
Potential Market Applications
CroíValve – DUO™ Adapt System
Spinout Origin: Trinity College Dublin
Clinical Stage: TANDEM II Study
Market Applications
• Structural heart disease treatment: Minimally invasive therapy for severe tricuspid regurgitation patients who may not qualify for open-heart surgery.
• Transcatheter valve intervention platforms: Next-generation catheter-based technologies reducing procedural complexity and expanding patient eligibility.
• Cardiovascular device innovation: Adaptive heart valve systems capable of addressing complex anatomical variations in large patient populations.
Related Topics:
medical device commercialization, university spinouts, structural heart innovation, transcatheter therapies, venture-backed medtech, clinical-stage startups
